Merck & Company Inc.

Sunrun, UnitedHealth, and Tonix Pharmaceuticals dominate the conversation

Plus: The latest economic data is in. See more.

Here's how one surprise move could upend Big Pharma’s playbook.

President Trump and Elon Musk continue to feud. Nike and Apple boost the Dow.

The President is scheduled to sign an Executive Order on Monday to upend the entire pharmaceutical industry.

But Alphabet's bullish earnings cheer investors. Tariff worries persist even as president insists many trade deals are close.

Stocks finished higher as investors look beyond their concerns about tariffs and a possible trade war.

The Dow's biggest losers include companies in the aerospace, biopharma, and sports apparel sectors.

Stocks generally enjoyed one of the best months of the year. Here's what else you should know about the markets into year-end.

Another leg higher in Treasury bond yields is muting stock gains heading into a busy earnings session on Wall Street.

Tech's market dominance waned in the third quarter.

Here are the stocks making the biggest market moves today.

Stocks are down despite higher consumer confidence.

Wall Street will navigate a busy Tuesday session of earnings and data with updates from AMD and Microsoft due after the closing bell.

The Fed meets, a jobs report is ahead, along with earnings reports from Microsoft, Apple, Meta and Amazon.

Here's what could happen to interest rates next.

Wall Street is looking to extend its recent rally ahead of the first of the Big Six big tech earnings after the closing bell.

Stocks could slump if this report shows inflation heating up.

After a big week with record closes, investors face the Fed, a jobs report and earnings from Facebook parent Meta, Microsoft, Apple, Alphabet and Amazon.

Let's look at how to read the government closure; also a look at the tech trade, Oklo and Nvidia.

Let's look at the Mag 7 names individually for clues. Plus, another market oddity, my 'down and out' radar draws me to one chart, and a couple of stocks I've recommended go vertical.

Novo Nordisk has gotten oversold and actionable. Here's how to trade it.

Let's take a look at the continuing 'no follow-through' group rotation, whether we saw a false breakout, and what this market is vulnerable to. Plus, Rocket Lab, Lilly, Merck and more.

There are multiple reasons to like this mid-cap concern. Here's how to trade it.

Today was one of those days. What's next?

While large-cap pharma stocks disappoint, these lesser-known names are gaining strength.

We rang the register and exited one position, fortifying our cash levels for opportunities down the line.

Let's check the hit from the ISM numbers -- ouch -- and the India tariffs; also, I chart the market, look at the Fed Chair ... options ... and Advanced Micro Devices.

I'm eyeing these names as they're getting consistent growth and upping guidance, making them likely buyout targets.

Challenges are mounting for the pharma giants that have come to rely on foreign imports.

This is where we realize we may be up against something. Let's discuss the big pharma beat-down, the big tariff story, the S&P chart, Apple, Amazon and Palantir. Oh, and it's jobs day.

There has been a minor change in the indicators.

Check out these charts of Rocket Lab, all eyes are back on a China deal and the Fed, the semiconductors rise with AMD.

Trump strikes a trade agreement with Europe, S&P 500 and Nasdaq Composite finish the week with fresh highs, and brace for the data and earnings deluge.

Both reports confirm AI adoption is unfolding, offering support for other Portfolio holdings.

Bulls continue to ignore tariff concerns and run over economic bears.

Plus, 10 biotech stocks on my radar as the sector may finally be ready to shine.

Guidance is already starting to shake on trade uncertainty; also, WPP warns on advertising spend, Morgan Stanley scores an M&A win, Wall Street price targets.

The investment firm's analysts share their views about the precious metal.

UnitedHealth, still reeling from the murder of one of its top executives, is reportedly facing a Department of Justice investigation.

The federal agency has opted to make a drastic decision during a critical time of the year.